Karuna Therapeutics, Inc., A Bristol Myers Squibb Company

This study looks at the long-term safety of a drug called KarXT for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). About 800 people who completed earlier studies will take KarXT for up to 52 weeks. Researchers will track side effects to see…

This study looks at the long-term safety of adding KarXT (a combination of two drugs) to current antipsychotic treatment for adults with schizophrenia whose symptoms are not well controlled. About 280 participants who completed a previous study will take KarXT twice daily for 52 …

This study checks the long-term safety of KarXT in teens (13-17) with schizophrenia and KarXT plus KarX-EC in children (5-17) with irritability linked to autism. About 400 participants who completed earlier studies will take the drug for up to 2 years. Researchers will monitor si…

This study tests an experimental drug called KarXT to see if it can prevent the return of psychosis (hallucinations, delusions) in people with Alzheimer's disease. About 410 participants aged 55-90 will receive either KarXT or a placebo for 38 weeks. The goal is to see if KarXT h…

This study tests a drug called KarXT to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. About 500 participants aged 55 to 90 with mild to severe Alzheimer's and moderate to severe psychosis will receive either KarXT or a placebo. The g…

This study tests an experimental drug called KarXT to see if it can safely reduce psychosis symptoms like hallucinations and delusions in people with Alzheimer's disease. About 406 adults aged 55 to 90 with mild to severe Alzheimer's and moderate to severe psychosis will take eit…

This study looks at how much of the drug KarXT gets into the breast milk and blood of healthy women who are breastfeeding. Eight mothers will take KarXT and provide milk and blood samples over 24 hours. The goal is to estimate how much of the drug a nursing baby might receive and…

This study looks at how the drug KarXT is broken down in healthy adults who have different types of a liver enzyme called CYP2D6. About 56 participants will be grouped by their metabolism speed (normal, intermediate, poor, or ultrarapid). The goal is to measure drug levels and sa…

This study looks at how a new drug called KarXT affects the levels of three other medicines (midazolam, fexofenadine, and digoxin) in the blood of healthy adults. Researchers want to see if taking KarXT changes how these drugs are processed by the body. The results will help guid…